Public Sector Pension investment Board Lowers Stake in AMAG Pharmaceuticals, Inc. (AMAG)

Public Sector Pension investment Board reduced its stake in shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) by 28.3% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 17,700 shares of the specialty pharmaceutical company’s stock after selling 7,000 shares during the period. Public Sector Pension investment Board owned approximately 0.05% of AMAG Pharmaceuticals worth $326,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the company. GSA Capital Partners LLP lifted its stake in shares of AMAG Pharmaceuticals by 98.7% during the second quarter. GSA Capital Partners LLP now owns 93,000 shares of the specialty pharmaceutical company’s stock worth $1,711,000 after buying an additional 46,200 shares during the period. PNC Financial Services Group Inc. lifted its stake in shares of AMAG Pharmaceuticals by 2.7% during the second quarter. PNC Financial Services Group Inc. now owns 18,766 shares of the specialty pharmaceutical company’s stock worth $346,000 after buying an additional 486 shares during the period. Nationwide Fund Advisors lifted its stake in shares of AMAG Pharmaceuticals by 12.4% during the second quarter. Nationwide Fund Advisors now owns 52,624 shares of the specialty pharmaceutical company’s stock worth $968,000 after buying an additional 5,800 shares during the period. Ameriprise Financial Inc. lifted its stake in shares of AMAG Pharmaceuticals by 0.8% during the second quarter. Ameriprise Financial Inc. now owns 185,457 shares of the specialty pharmaceutical company’s stock worth $3,412,000 after buying an additional 1,521 shares during the period. Finally, TIAA CREF Investment Management LLC lifted its stake in shares of AMAG Pharmaceuticals by 39.7% during the second quarter. TIAA CREF Investment Management LLC now owns 173,023 shares of the specialty pharmaceutical company’s stock worth $3,184,000 after buying an additional 49,209 shares during the period.

Several equities research analysts have recently commented on the stock. BidaskClub upgraded shares of AMAG Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, July 6th. Citigroup Inc. decreased their target price on shares of AMAG Pharmaceuticals to $24.00 and set a “hold” rating for the company in a research report on Friday, July 7th. Zacks Investment Research downgraded shares of AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, July 26th. Cowen and Company restated a “hold” rating on shares of AMAG Pharmaceuticals in a research report on Thursday, August 10th. Finally, Deutsche Bank AG set a $24.00 target price on shares of AMAG Pharmaceuticals and gave the company a “hold” rating in a research report on Friday, July 7th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and four have given a buy rating to the company’s stock. AMAG Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $27.67.

ILLEGAL ACTIVITY WARNING: “Public Sector Pension investment Board Lowers Stake in AMAG Pharmaceuticals, Inc. (AMAG)” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The legal version of this story can be accessed at https://www.com-unik.info/2017/10/13/public-sector-pension-investment-board-lowers-stake-in-amag-pharmaceuticals-inc-amag.html.

AMAG Pharmaceuticals (NASDAQ:AMAG) last released its earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.58) by $0.18. AMAG Pharmaceuticals had a negative net margin of 7.58% and a negative return on equity of 4.81%. The company had revenue of $158.39 million during the quarter, compared to analysts’ expectations of $158.83 million. During the same quarter last year, the business earned $1.45 EPS. The business’s revenue was up 24.3% on a year-over-year basis.

AMAG Pharmaceuticals Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Institutional Ownership by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

What are top analysts saying about AMAG Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AMAG Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit